Ocular Therapeutix (OCUL) Return on Capital Employed (2014 - 2026)
Ocular Therapeutix's (OCUL) quarterly Return on Capital Employed came in at 41.44% in Q1 2026, up 1036.0% year-on-year from 3.65% in Q1 2025, and up 14.26% quarter-over-quarter from 48.33% in Q4 2025.
Ocular Therapeutix (OCUL) Return on Capital Employed (2014 - 2026) Analysis & Trends
Ocular Therapeutix's Return on Capital Employed history runs 13 years deep, the most recent figure standing at 41.44% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 1036.0% year-over-year to 41.44% in Q1 2026; TTM through Mar 2026 was 41.44%, a 1036.0% increase from a year earlier, with the FY2025 full-year figure at 46.38%, up 839.0% from the prior year.
- Return on Capital Employed improved to 41.44% in Q1 2026 per OCUL's latest filing, from 48.33% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 22.98% in Q2 2024 and bottomed at 90.15% in Q2 2023.
- The 5-year median for Return on Capital Employed is 48.84% (2022), against an average of 52.23%.
- Across the five-year window, Return on Capital Employed plunged 4131 bps in 2023 and soared 6716 bps in 2024, its largest moves.
- Year by year, Return on Capital Employed stood at 64.19% in 2022, then advanced by 26 bps to 47.81% in 2023, then rose by 17 bps to 39.69% in 2024, then fell by 22 bps to 48.33% in 2025, then advanced by 14 bps to 41.44% in 2026.
- Per Business Quant, the three latest OCUL Return on Capital Employed figures stand at 41.44% (Q1 2026), 48.33% (Q4 2025), and 65.69% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Ocular Therapeutix | 1.93 Bn | 1.93 Bn | 9.46 Mn | -41.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.44% |
| Dec 31, 2025 | -48.33% |
| Sep 30, 2025 | -65.69% |
| Jun 30, 2025 | -59.15% |
| Mar 31, 2025 | -51.80% |
| Dec 31, 2024 | -39.69% |
| Sep 30, 2024 | -30.22% |
| Jun 30, 2024 | -22.98% |
| Mar 31, 2024 | -24.64% |
| Dec 31, 2023 | -47.81% |
| Sep 30, 2023 | -76.06% |
| Jun 30, 2023 | -90.15% |
| Mar 31, 2023 | -76.33% |
| Dec 31, 2022 | -64.19% |
| Sep 30, 2022 | -56.64% |
| Jun 30, 2022 | -48.84% |
| Mar 31, 2022 | -43.90% |
| Dec 31, 2021 | -42.19% |
| Sep 30, 2021 | -37.34% |
| Jun 30, 2021 | -31.96% |